The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.
 
Keun Wook Lee
Honoraria - BMS; Genexine; Lilly
Consulting or Advisory Role - Bayer; ISU ABXIS
Research Funding - ABL Bio (Inst); ALX Oncology (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); Green Cross (Inst); LSK BioPharma (Inst); Macrogenics (Inst); Merck KGaA (Inst); MSD (Inst); Oncologie (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Pharmacyclics (Inst); Taiho Pharmaceutical (Inst); Y-BIOLOGICS (Inst); Zymeworks (Inst)
 
Young-Hyuck Im
No Relationships to Disclose
 
Keun Seok Lee
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Roche
Research Funding - Dong-A ST (Inst)
 
Jae Yong Cho
No Relationships to Disclose
 
Do-Youn Oh
Consulting or Advisory Role - ASLAN Pharmaceuticals; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Genentech/Roche; Halozyme; Merck Serono; Novartis; Taiho Pharmaceutical; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Lilly; MSD; Novartis; SERVIER
 
Hyun Cheol Cheol Chung
Consulting or Advisory Role - Amgen; Beigene; Bristol-Myers Squibb; Celltrion; Gloria Biosciences; Lilly; Merck Serono; MSD; Quintiles; Taiho Pharmaceutical; Zymeworks
Speakers' Bureau - Foundation medicine; Lilly; Merck Serono
Research Funding - Amgen (Inst); Beigene (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Taiho Pharmaceutical (Inst); Zymeworks (Inst)
 
Yee Chao
No Relationships to Disclose
 
Li-Yuan Bai
Honoraria - Lilly; Pfizer; SynCoreBio
Consulting or Advisory Role - Bristol-Myers Squibb
 
Chia Jui Yen
No Relationships to Disclose
 
In-Ho Kim
No Relationships to Disclose
 
Sang Cheul Oh
No Relationships to Disclose
 
Chia-Chi Lin
Honoraria - Daiichi Sankyo; Lilly; Novartis; Novartis; Roche
Consulting or Advisory Role - Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo; Novartis
Travel, Accommodations, Expenses - BeiGene; Daiichi Sankyo; Daiichi Sankyo; Lilly; Novartis
 
Jin Wang
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Xin Wang
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Huiyan Li
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
Travel, Accommodations, Expenses - BeiGene
 
Yen-Yang Chen
No Relationships to Disclose
 
Yoon-Koo Kang
Consulting or Advisory Role - ALX Oncology; Amgen; Bristol-Myers Squibb; DAEHWA Pharmaceutical; Macrogenics; Novartis; Surface Oncology; Zymeworks